Physician profile
Richard E Lavigne
NPI 1770575896
$7,611.87
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,367 · 2020: $1,264 · 2021: $1,714 · 2022: $1,801 · 2023: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $466.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,528.87 | 2019-2023 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $764.08 | 2019-2023 | Farxiga |
| Glaxosmithkline, LLC. | $669.49 | 2019-2023 | Shingrix, Bexsero, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $612.91 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $500.20 | 2019-2021 | |
| Abbvie INC. | $484.56 | 2019-2022 | |
| Pfizer INC. | $350.54 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $250.80 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $213.53 | 2019-2023 | |
| Lilly USA, LLC | $199.64 | 2019-2023 | Jardiance, Lyumjev |
| Sanofi-Aventis U.S. LLC | $193.09 | 2019-2022 | |
| Abbott Laboratories | $181.55 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $169.56 | 2019-2023 | Eliquis |
| Amgen INC. | $153.85 | 2019-2023 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.94 | 2021-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Lavigne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.